Monopar Therapeutics Inc
$ 77.19
1.64%
03 Dec - close price
- Market Cap 515,795,000 USD
- Current Price $ 77.19
- High / Low $ 79.65 / 74.00
- Stock P/E N/A
- Book Value 21.25
- EPS -3.96
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.18 %
- ROE -0.26 %
- 52 Week High 105.00
- 52 Week Low 20.61
About
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Wilmette, Illinois, dedicated to developing proprietary therapies that enhance clinical outcomes for cancer patients. The company boasts a diverse pipeline of innovative drug candidates aimed at addressing critical unmet needs in oncology. By employing advanced drug formulation technologies to improve treatment efficacy and safety, Monopar is strategically positioned to make significant contributions to cancer care and establish itself as a prominent entity in the biopharmaceutical landscape.
Analyst Target Price
$111.77
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-12 | 2025-05-07 | 2025-03-26 | 2024-11-07 | 2024-08-09 | 2024-05-09 | 2024-03-28 | 2023-11-09 | 2023-08-10 | 2023-05-11 | 2023-03-23 |
| Reported EPS | -0.48 | -0.35 | -0.38 | -2.75 | -0.37 | -0.5 | -0.1 | -0.12 | -0.14 | -0.16 | -0.19 | -0.23 |
| Estimated EPS | -0.3989 | -0.09 | -0.5667 | -0.42 | -0.48 | -0.47 | -0.12 | -0.15 | -0.17 | -0.18 | -0.22 | -0.2 |
| Surprise | -0.0811 | -0.26 | 0.1867 | -2.33 | 0.11 | -0.03 | 0.02 | 0.03 | 0.03 | 0.02 | 0.03 | -0.03 |
| Surprise Percentage | -20.3309% | -288.8889% | 32.9451% | -554.7619% | 22.9167% | -6.383% | 16.6667% | 20% | 17.6471% | 11.1111% | 13.6364% | -15% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MNPR
2025-10-16 20:44:44
Raymond James has increased its price target for Monopar Therapeutics (MNPR) to $142 from $80, reaffirming a Strong Buy rating, with expectations for continued strong performance into 2026. This comes after the company reported a net loss of $2.5 million in Q2 2025, an increase from $1.7 million in Q2 2024, but with sufficient cash reserves to fund operations until December 31, 2026. The firm's confidence is based on Monopar's projected milestones, including an NDA filing for ALXN1840 and advancements in its MNPR-101 programs.
2025-10-15 12:14:00
Monopar Therapeutics Inc. announced an oral presentation at AASLD 2025 for its Phase 2 study on ALXN1840 (Tiomolybdate Choline) in Wilson Disease, highlighting "Rapidly Improved Cu Balance." The presentation will occur on November 9, 2025, by Aftab Ala, and will cover significant findings from the copper balance study. The company also disclosed potential positives, negatives, and details about insider trading activities and analyst ratings for its stock, MNPR.
2025-10-15 12:00:00
Monopar Therapeutics (NASDAQ: MNPR) announced that its abstract from the Phase 2 ALXN1840-WD-204 copper balance study has been accepted for an oral presentation at AASLD – The Liver Meeting® 2025. The presentation, titled "Rapidly Improved Cu Balance in Wilson Disease Patients on Tiomolybdate Choline," will be given by Aftab Ala on November 9, 2025, and will discuss the rapid improvement of copper balance in Wilson Disease patients. This highlights the company's progress in developing treatments for unmet medical needs.
2025-10-14 05:23:26
Monopar Therapeutics (NASDAQ:MNPR) shares surged 16.3% following an analyst upgrade. The article details recent insider stock sales, institutional investor activities, and the company's current financial metrics. Monopar Therapeutics is a clinical-stage biopharmaceutical company focusing on cancer treatments.
2025-10-13 09:54:24
Barclays analyst Etzer Darout initiated coverage of Monopar Therapeutics (MNPR) with an Overweight rating and a $125 price target. The firm began coverage of eight companies in various medical fields, noting that small- and mid-cap biotechnology names with de-risked mechanisms of action present favorable risk/reward profiles. Barclays believes the market is valuing new mechanisms that could improve dosing frequency and patient compliance.
2025-10-12 05:13:11
Jones Trading upgraded Monopar Therapeutics (NASDAQ:MNPR) from a "hold" to a "strong-buy" rating. Several other research firms have also issued positive ratings and price targets for MNPR. This report also details recent insider selling activity and institutional investor holdings in Monopar Therapeutics.
